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Drug-eluting stents (DES) are coated stents capable of releasing single or multiple
bioactive agents into the bloodstream and surrounding tissues. Stents represent a major
advance in the treatment of obstructive coronary artery disease since the advent of bal-
loon angioplasty. Angioplasties have doubled in Europe from 1992–1996. Much research
has been devoted to the pathophysiology and treatment of in-stent restenosis.
Disease-induced narrowing in the fluid-carrying vessels of the human body can oc-
cur in a wide variety of circumstances. For example, blockages in the vascular system
can deprive the downstream tissue of oxygenated blood, constrictions of the urinary
tract can lead to pain and loss of renal function, and biliary duct blockages can lead to
pathologic jaundice. In the past, open surgical approaches were used to solve these
problems, but more recently, stents have been used; a stent may be defined as a device
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Drug-eluting stents (DESs) prevail in the treatment of ca-
rotid artery diseases in the interventional cardiology world
owing to their efficacy for significant reduction of reste-
nosis. A current successful DES requires a polymer coat-
ing for drug delivery. Clinical trials examining several
pharmaceutical agents have demonstrated marked reduc-
tion in restenosis following stenting. The development
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that is intended to keep a biological passageway open. Most often stents take the form of
cylindrically shaped devices that press out against the vessel or duct wall thereby restor-
ing patency (patency of a vessel or duct refers to it being open or unobstructed). Since
the early 1990s, stents have revolutionized the treatment of vascular diseases; they were
first reported for use in restoring patency in the coronary artery. Since then, their use has
accelerated to the degree that 1.5 million cardiovascular stenting procedures are perfor-
med in the United States annually (1).
However, three types of post-stent narrowing of the vessel may occur:
(i) The compressive force created by the vessel may cause elastic recoil of the stent
and an associated immediate narrowing of the lumen.
(ii) Injury caused by stent deployment may initiate intimal hyperplasia (IH), whe-
reby smooth muscle cells in the vessel wall proliferate into the lumen (the inner
part of the vessel) causing a process of re-stenosis to occur over time.
(iii) Remodeling of the vessel wall may occur as the stiffness of the vessel wall
changes in response to the stresses generated in the tissue and the vessel nar-
rows, termed »negative« remodeling.
Renarrowing of a stented vessel is termed in-stent restenosis (ISR) and it involves
the formation of IH though a complex cascade of post-stenting cellular events (2).
Restenosis rates, or binary restenosis rates, are defined by the number of stented
vessels that have over 50 % vessel lumen stenosis at follow-up post-stenting; they have
been reported for many different stent designs from the results of clinical trials. Based
on 20–50 % restenosis rates in some stent designs, drug-eluting stents were developed in
the early 2000s.
Drug-eluting stents have shown superior performance in prevention of in-stent re-
stenosis; one of the key clinical trials showed a reduction from 26.6 % for the bare-metal
stents to 7.9 % for the drug-eluting stents. A stent should be sufficiently flexible in bend-
ing during expansion to not unduly straighten curved vessels; it must have sufficient
scaffolding properties (i.e., there should be minimal prolapse or »draping« of the inner
lumen between the struts of the expanded stent, and stenotic material should not be so
highly stressed to make a part of it break off); the amount of shearing of the metal stent
over the vessel wall during expansion should be minimized as such shearing could de-
nude the vessel wall of its endothelial cell lining; the stent should not foreshorten during
expansion (i.e., the degree of longitudinal contraction during expansion should be as
small as possible).
Drug-eluting stents deliver potentially high doses of drugs locally for variable time
periods in the area of stent implantation directed to the potential restenosis site. While
this is currently achievable, optimal pharmacological therapy is still evolving. Neointi-
ma proliferation, the prime cause of restenosis in stent error, is the result of a local injury
response modulated by platelet and fibrinolytic effects, inflammation as well vascular
(endothelial) healing. Choosing the optimal drug(s) and doses for stent delivery will re-
quire testing to optimally prevent proliferation while enhancing healing. The time course
of drug delivery is also important. Finally, potential complications must be evaluated.
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WHY DRUG-ELUTING STENTS?
In 1991, stent use was still facing skepticism because of an unacceptably high (20 to
25 %) incidence of thrombotic complications (3). Systemic anticoagulation proved disap-
pointing in reducing the catastrophic consequences of stent thrombosis, such as myocar-
dial infarction and sudden death. Consequently, antithrombotic stent coatings were de-
veloped to decrease the inherent thrombogenicity of coronary metallic stents. Some
heparin-coated stents became available for clinical use. Heparin-coated stents differ
from drug-eluting stents because the medication is covalently bonded to the device and
hence may remain attached long after deployment. These stents represented the first
step toward loading medications onto stents. Fortunately, the incidence of subacute stent
thrombosis has dropped significantly to 0.5 % because of high-pressure stent deployment
and the use of antiplatelet agents (4).
STEPS INVOLVED IN MANUFACTURING DRUG-ELUTING STENTS
In clinical practice, the operator must decide which stent is most appropriate for the
patient, and even more importantly, for the lesion that is going to be treated. General
characteristics pertaining to the »ideal« stent are listed in the following:
 flexible,
 trackable,





 high radial strength,
 circumferential coverage,
 low surface area,
 hydrodynamic compatible.
Stents can be wound coils, woven mesh designs, or laser-cut designs. Most stents
available today are laser-cut stents and the closed-cell types are slotted tubes whereby
the stent geometry is machined from a full cylinder so that no welds exist in the struc-
ture; examples include the NIR, Be Stent, and inflow stent designs.
FABRICATION TECHNIQUES
The choice of fabrication method mainly depends on the raw material form used.
Wires can be formed into stents in various ways using conventional wire-forming tech-
niques, such as coiling, braiding or knitting. The simplest shape for a wire stent is a coil.
All coil stents marketed today are made of nitinol and are self-expanding. Welding at
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specific locations after wire forming produces closed-cell wire stents or increases longi-
tudinal stability.
The vast majority of coronary stents, and probably the majority of peripheral vascu-
lar stents, are produced by laser cutting from tubing. Balloon-expandable stents are cut
in the crimped or near-crimped condition, and only require post-cutting deburring and
surface treatment, typically electro-polishing.
Step I
The carrier stent. – Endovascular stents were initially designed as scaffolding struc-
tures, not medication-delivery devices. Consequently, stent design has been altered to
afford more flexibility, greater radial strength, and minimal metallic coverage. Efforts are
now directed at coating a stent with a sufficient amount of medication that can be deliv-
ered uniformly to the underlying tissue. Uniform drug distribution in human, diseased
coronary arteries is unrealistic, however. Besides stent design, other factors govern drug
diffusion, such as vessel wall morphology, drug physicochemical characteristics, and the
multifaceted milieu of the underlying atherosclerotic plaque.
Compared with current stents, the ideal drug-delivery stent might have a much
larger surface area, minimal gaps between cells, and minimal strut deformation after de-
ployment.
Step II
The coating matrix is a double edged sword. – There are several approaches to coating
stents with medications. Some drugs can be loaded directly onto metallic surfaces (e.g.,
prostacyclin, paclitaxel), but a coating matrix that contains the medication is required for
most biological agents (Fig. 1). The coating ensures drug retention during deployment
and modulates drug-elution kinetics.
In theory, sustained release of anti-restenotic drugs for at least 3 weeks after deploy-
ment is required to prevent smooth muscle cell migration and proliferation. Drugs may
be held by covalent bonds (e.g., C-C bonds, sulfur bridges) or non-covalent bonds (e.g.,
ionic, hydrogen bonds) (5). The blended matrix may then be attached to the stent surface
by dipping or spraying the stent.
Drug is released by particle dissolution or diffusion when non-bioerodable matrices
are used, or during polymer breakdown when incorporated (absorbed) into a biodegra-
dable matrix. The coating material should act as a biologically inert barrier. Selection of
a non-inflammatory, inert coating matrix has been a major obstacle to the development
of drug-eluting stents. Coating materials must maintain their physicochemical charac-
teristics after sterilization and after stent expansion. These substances may be catego-
rized as organic, inorganic, bioerodable, non-bioerodable, synthetic, or naturally occur-
ring substances (6).
Synthetic polymers. – To date, the most successfully tested drug-eluting stents have
been coated with synthetic polymers: poly-n-butyl methacrylate and polyethylene–vinyl
acetate with sirolimus, and a poly(lactide-co-caprolactone) copolymer with paclitaxel
eluting platforms (7).
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Biological materials. – The surfaces of a vascular prosthesis must be both bio- and
hemo-compatible (8). Fibrin, cellulose, and albumin, all naturally occurring, have been
tested to improve the quality of stent surfaces, with promising results from animal studies.
Inorganic coatings. – Inorganic substances have been placed on stent surfaces to im-
prove their electromechanical properties. In addition, other ongoing studies involve stents
designed with a deep reservoir for drug loading coated with a thin layer of pyrolytic
carbon (Carbofilm).
Step III
The biological agent. – The ideal anti-restenotic agent for local delivery should have
potent anti-proliferative effects and yet preserve vascular healing. Such a compound should
contain hydrophobic elements to ensure high local concentrations, as well as hydrophi-
lic properties to allow homogeneous drug diffusion. Other factors such as molecular
mass, charge, and degree of protein binding may also affect drug kinetics and ultimately
influence the biological success (9).
Anti-cancer and anti-transplant rejection agents are now being considered in the
fight against restenosis drugs that interfere earlier in the cell cycle (G1 phase); they are
generally considered cytostatic and potentially elicit less cellular necrosis and inflamma-
tion compared to agents that affect the cell cycle at a later stage (beyond the S phase)
(10). On the basis of the mechanism of action of the biological compound and its target
in the restenotic process, drug-eluting stents may be generally classified as immunosup-
pressive, anti-proliferative, anti-inflammatory, anti-thrombotic, and prohealing.
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Fig. 1. Schematic representation of different modalities of drug-eluting stent platforms (black repre-
sents stent strut; gray, coating). A) drug-polymer blend, release by diffusion, B) drug diffusion through
additional polymer coating, C) drug release by coating swelling, D) non-polymer-based drug re-
lease, E) drug loaded in stent reservoir, F) drug release by coating erosion, G) drug loaded in na-
noporous coating reservoirs, H) drug loaded between coatings (coating sandwich), I) polymer-drug
conjugate cleaved by hydrolysis or enzymatic action, J) bioerodable polymeric stent.
DESIGN NECESSITIES OF STENTS
Intravascular stents, whether expanded using a balloon or self-expanding, are de-
livered via femoral or brachial arteries through the tortuous vessels of the cardiovascular
system. To minimize in-stent restenosis, stents must fulfil the following expanded list of
design requirements:
(i) High radial strength: Required radial support/structural strength to prevent
vessel recoil and hence lumen loss post-stenting.
(ii) Ameasure of elastic recoil: It may be defined by (Rload-Runload)/Rload, whe-
re R represents the radius of the stented vessel for full balloon expansion (load)
and after deflation of the balloon (unload).
(iii) Good flexibility: The crimped stent on the delivery catheter must be flexible so
that it can be delivered to the deployment site.
(iv) Low stent profile: The crimped stent on the delivery catheter should have a low
profile to prevent excessive flow disturbances during delivery and once deplo-
yed.
(v) Good trackability: Trackability is a measure of the ability of a stent deployment
catheter to follow the tortuous path to its ultimate destination. Trackability de-
pends on shaft flexibility, which should be high, friction between the stent and
its surrounding environment, which should be low to prevent damage to the
vessel wall and hinder the movement of the catheter, axial stiffness, which
should be high so as to reduce axial deformation of the catheter.
(vi) Minimal foreshortening: The measure of foreshortening may be defined by
(Lload)/L, where L represents the length of the stent before deployment, and
Lload, the length of the stent after balloon inflation.
(vii) Minimal elastic longitudinal recoil: Foreshortening and longitudinal recoil may
also cause undesirable shearing along arterial walls, which can cause injury in
the form of denudation of the endothelial cells from the lumen of the vessel
during stent expansion.
(viii)Optimum scaffolding: A stent should provide optimum vessel coverage to en-
sure that the vessel tissue does not prolapse between the stent struts; however,
a low artery-stent contact surface area should also be maintained, because the
foreign material of the stent can initiate an aggressive thrombotic response.
(ix) Stent material requirements:
 Radiopacity: Stent materials need to be radiopaque to enable delivery, pre-
cise positioning, and evaluation of stents in follow-up under the guidance of
fluoroscopic imaging.
 Biocompatible: Stent materials must be biocompatible so as not to elicit an
adverse reaction from the body.
 Corrosion-resistant: Stent materials are chosen which prevent corrosion by
the development of a passive oxide layer.
 Good fatigue properties: Cyclic stresses because of blood flow can cause fa-
tigue failure in stents (11).
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All of these design requirements can be achieved by optimizing the following pa-
rameters:
(i) material selection,
(ii) strut dimensions and cross-section,
(iii) number of circumferential and axial repeating units, and their geometry,
(iv) the manufacturing process used to produce stents.
STENT DESIGN
Geometry of stent platforms
The subsequent evolution of stent design yielded the development of a rich variety
of stent geometries, which can be classified into five main high-level categories: coil, he-
lical spiral, woven, individual rings or sequential rings (12).
Coil. – Most common in non-vascular applications, as the coil design allows for re-
trievability after implantation. These designs are extremely flexible, but their strength is
limited and their low expansion ratio results in high profile devices (13).
Helical spiral. – These designs are generally promoted for their flexibility. With no or
minimal internal connection points, they are very flexible, but lack longitudinal support.
As such, they can be subject to elongation or compression during delivery and deploy-
ment and, consequently, irregular cell size formation.
Woven. – This category includes a variety of designs constructed from one or more
strands of wire. Braided designs are often used for self-expanding structures.
Individual rings. – Single »Z« shaped rings are commonly used to support grafts or
similar prostheses; they can be individually sutured or otherwise attached to the graft
material during manufacture. These structures are not typically used alone as vascular
stents.
Sequential rings. – This category describes stents comprising a series of expandable
Z-shaped structural elements (known as »struts«) joined by connecting elements (known
as »bridges«, »hinges«, or »nodes«).
Closed cell. – These U-, V-, S-, or N-shaped elements plastically deform during bend-
ing, allowing adjacent structural members to separate or nest together, to more easily ac-
commodate changes in shape. The primary advantages of closed-cell designs are opti-
mal scaffolding and a uniform surface, regardless of the degree of bending. However,
these advantages result in a structure that is typically less flexible than a similar open-
-cell design.
Open cell. – This category describes construction wherein some or all the internal in-
flection points of the structural members are not connected by bridging elements. This
allows periodic peak-to-peak connections, peak-to-valley connections, and mid-strut to
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mid-strut connections, as well as innumerable hybrid combinations. In open-cell de-
signs, the unconnected structural elements contribute to longitudinal flexibility. Periodi-
cally connected peak-to-peak designs are common among self-expanding stents, such as
the SMART stent, as well as balloon-expandable stents, such as the AVE S7.
Consequently, structures with this type of peak-to-valley connection are generally
not so strong as similar structures with peak-to-peak connections. While this peak-to-
-peak and peak-to-valley connections are the most common, there are also examples of
other variations, such as the BeStent, which feature mid-strut to mid-strut connectors.
MATERIALS FOR STENT CONSTRUCTION
Stent materials clearly need to be biologically inert and radiopaque to enable visual-
ization of stent deployment. All stent materials also need to be corrosion-resistant to
withstand the highly corrosive environment of the body. The material chosen for a stent
depends on the expansion mechanism of the stent, since self-expanding stents must be
able to recover considerable elastic deformation and balloon-expanding stents need to
deform plastically during deployment. Nickel-titanium alloy and nitinol are the most
commonly used material for self-expanding examples RADIUS (Scimed, Singapore)
stent and the Medtronic AneuRx AAA Stent Graft (Medtronic, USA). Other materials
that have been used in self-expanding stents include a platinum core with a cobalt alloy
as the outer layer, which has been used for the mesh of the Wallstent (Boston Scientific,
USA).
The most widely used material for balloon-expandable stents is 316L stainless steel,
a low carbon (0.03 % maximum) steel that has a high chromium content (17–20 %) and
molybdenum (2–4 %) to prevent pitting corrosion in saline solutions. Stents made of
316L stainless steel include the first coronary stent (14). Tantalum Crossflex stent (Cordis
Corporation, USA) is a highly radiopaque material, but it has not been used extensively
because it is very brittle and therefore more prone to fracture than stainless steel (15).
Cobalt chromium has been used for stents in recent years, including the Multilink Vision
(Guidant, USA) and Driver stents (Medtronic Vascular, USA), to enable stents with thin-
ner struts to be designed, because cobalt chromium alloys have higher strength than
stainless steel.
POLYMERIC POSSIBILITIES
Materials for polymer stents include biodegradable stents coupled with polymeric
endoluminal paving, and shape-memory polymers. Silicone was the first organic material
chosen for stenting. However, silicone has poor biodurability, tensile and coil strength,
and inner to outer diameter ratio (16).
Pure plastic biliary stents using polyethylene or polyurethane have also been used
in patients. However, polyethylene induces sludge in 20-30 % of patients, encourages
protein adherence and biofilm formation, and entraps bile crystals and food particles. In
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contrast, polyurethane has good tensile and coil strength, and good biodurability, but it
is also one of the most reactive materials available (17).
Biodegradable and bioabsorbable polymers. – Biodegradable and bioabsorbable stents
are also viable materials for stenting. Though biodegradation, bioabsorption, and bio-
erosion are often used incorrectly as synonyms, they have different definitions. In biode-
gradation, a biological agent like an enzyme or a microbe is the dominant component in
the degradation process. Biodegradable implants are usually useful for short-term or
temporary applications. Bioresorption and bioabsorption imply that the degradation
products are removed by cellular activity, such as phagocytosis, in a biological environ-
ment. In contrast, a bioerodible polymer is a water-insoluble polymer that has been con-
verted under physiological conditions into water-soluble materials. This occurs regard-
less of the physical mechanism involved in the erosion process. Because of a stent’s
temporary structural support to damaged blood vessels, biodegradable polymers can be
viewed as a biocompatible, yet easily disposable material, perfect for drug delivery sys-
tems. Some biodegradable polymers, such as polyesters, polyorthoesters, and polyan-
hydrides, may be able to modulate the local delivery of drugs and also degrade »safely«
via hydrolytic and other mechanisms. Biodegradable drug delivery systems require stea-
dy degradation, permeability, and moderate tensile strength.
Also, anticoagulants and fibrinolytic agents can be bound directly to collagen, which
aids in its capacity for drug delivery. Some factors that accelerate polymer degradation
include providing the product with a more hydrophilic backbone, more hydrophilic
endgroups, less crystallinity, more porosity, and smaller overall size. The most common
chemical functional groups used are esters, anhydrides, orthoesters, and amides.
One concern in using biodegradable stents is the uneveness of the material remain-
ing after the degradation process. Various cells in the body are more likely to bind to un-
even surfaces and induce complications. One solution to this dilemma is to provide a
smooth surface by using polymeric endoluminal paving. In this process, biocompatible
polymers are applied to the surface of an organ or vessel. In »solid« or »structural pav-
ing,« tin tubes or sheets of biodegradable polymers are transported intraluminally or
intravascularly using a catheter, positioned at the deployment site, and locally remolded
with catheter-based thermoforming. »Gel paving« uses hydrogels which swell in the
presence of water, but eventually form adherent soft structural walls that develop effec-
tive drug delivery reservoirs. In liquid paving, flowable polymeric, macromeric, or pre-
-polymeric solutions are applied to the underlying tissue surface.
Shape memory polymers. – Once the polymer is synthesized, it may be heated or cool-
ed into myriad shapes. Upon introducing a suitable stimulus, the polymer will undergo
transition from its temporary state to a memorized, permanent shape. Most of these po-
lymers are created from suitable segments, primarily determined by screening the quali-
ties of existing aliphatic polyesters, especially poly(etherester), as well as L,L-dilactide,
diglycolide, and p-dioxanone. Toxicity of the shape-memory polymer system was mea-
sured using the chorioallantoic membrane test (CAM test). In this procedure, a sterilized
polymer film was incubated for two days in direct contact with the chorioallantoic mem-
brane of a fertilized chicken egg. Then the blood vessels on and around the film were ex-
amined. In the first tests performed, biodegradable multiblock polymers showed no in-
fluence on blood vessel growth and did not damage the underlying tissue (16).
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DRUG DELIVERY METHODS
How may drugs can be delivered in the context of stent implantation? There are
three basic routes. First, the drug may be absorbed into a suitable stent material itself,
which is intended to act like a sponge. Release of the drug is dependent upon diffusion
down a concentration gradient, or upon biodegradation of the stent material. Second,
the drug may be chemically bonded onto the surface of stent struts and released after
further chemical or biological action of the surrounding milieu or tissue. A combination
of this and the above approach may be attempted with a coating, for example a polymer
with the necessary tertiary structure, which may be used as a depot for the drug to be
held and released, the characteristics of uptake and release being controllable by the
composition of the coating 'elution' of the drug from the coating. Third, stent implanta-
tion and drug delivery can be treated as separate procedures. The three methods may be
combined. In this review, we will sub-divide stent-related local drug delivery into these
three categories.





In the diffusion-controlled systems the drug is dissolved or dispersed in a matrix
(Fig. 1). When it comes in contact with biological environment, the drug will diffuse out
of the carrier coating. Regarding the release profile, two different types of release sys-
tems can be differentiated. Matrix systems (Fig. 1, left) have a release rate that decreases
over time. But they are often continuous, of the so called zero-order release profile.
Reservoir systems (Fig. 1, right) have a fairly stable diffusion rate. They are built as
a core that contains the concentrated agent within a polymer matrix and a shell, and the
shell is made of a rate controlling material. The diffusion is driven by the concentration
gradient between the core and the outside of the shell or barrier coating.
Swelling-controlled release systems
Another option for drug release is the use of swelling-controlled materials. The ma-
terial with the drug is compact in the dry state and swells in contact with liquids. Cau-
sed by the swelling and often combined with a diffusion process, the incorporated drug
is released. The matrix and reservoir systems can be differentiated. Most of the materials
used in swelling-controlled release systems are based on hydro-gels. If there is a change
of pH, temperature, or ionic strength within the system, then it can either shrink or swell.
Biodegradable release systems
Caused by the biological degradation of the carrier material, the drug releases out
of the matrix. Depending on the type and mesh size of the material, diffusion plays a
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role too. Corresponding to the type of degradation, the systems are differentiated in
bulk and surface degradable systems. Surface degradable systems are favorable for drug
delivery systems in blood vessels because the risk of fragment formation and therefore
the risk of thrombosis caused by these fragments are minimized.
DRUG DELIVERY APPROACHES
Quality drug carriers can be made with lipids and polymers.
Lipids and liposomes
Some lipids are amphipathic molecules, for example, fatty acids, and phospholi-
pids. Lipids have a dual structure that contains a hydrophilic and a hydrophobic part.
They are soluble in organic solvents and form clusters in aqueous solutions. Monolayer,
micelles, and liposomes are the favored forms in aqueous solutions.
Liposomes are spherical lipid clusters consisting of one or more lipid bilayers en-
closing one or more aqueous compartments. They can mimic several properties of cell
membranes, for example, response to osmotic forces, have a permeability barrier, and
others. Liposomes are suitable as environmentally responsive systems for drug delivery.
Several chemical and physical triggers can stimulate drug release, such as light, electro-
magnetic field, pH, temperature, polyelectrolytes, etc.
Polymers
Many polymers are known to have the potential for drug delivery coatings. Whe-
ther a polymer is degradable or not depends on some chemical characteristics such as
molecular mass, hydrophobicity, etc. In reality, everything degrades, but the question is
how fast it degrades. For drug delivery applications, degradation on the human time
scale is important. Depending on the implantation site, more biocompatibility aspects
have to be considered for these polymers. Other potential disadvantages of polymeric
coatings are difficulties with the mechanical behavior after sterilization and expansion if
the implant undergoes high plastic deformation.
Hydrogels
Some materials, when placed in water, are able to swell very fast and retain aqueous
fluid up to the multiple of their own mass. These hydrogels are usually made of hydro-
philic polymer molecules cross-linked by chemical bonds or other cohesion forces such
as ionic interaction, hydrogen bonding, or hydrophobic interaction. Owing to their uni-
que bulk and surface properties, they show good biocompatibility and are favorable for
several drug delivery applications. They have no interfacial tension with the surround-
ing biological fluids and tissue, which minimize the driving force of protein adsorption
and cell adhesion. Furthermore, hydrogels simulate hydrodynamic properties of natural
biological gels, cells, and tissue in many ways.
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SELECTION OF DRUGS FOR STENTS
The drugs that may be useful in preventing ISR fall into four major categories: anti-
-neoplastics, immunosupressives, migration inhibitors, and enhanced healing factors.
ISR is primarily due to natural healing mechanisms, including endothelial cell migration
and extracellular matrix formation, collectively known as intimal hyperplasia. The dam-
aged tissue attracts platelets and they further exacerbate the endothelial cell response,
leading to thrombosis in the vicinity of the stent. Compounds that can inhibit ISR and
intimal hyperplasia are excellent candidates for drug eluting stents.
Table I gives a list of drugs in drug eluting stents.
Anti-proliferative drugs
Anti-proliferative compounds include paclitaxel, QP-2, actinomycin, statins and
many others. Paclitaxel was originally used to inhibit tumor growth by assembling mi-
crotubules that prevent cells from dividing. It has recently been observed to attenuate
neointimal growth as well.
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These agents are generally used to prevent the immune rejection of allogeneic organ
transplants. The general mechanism of action of most of these drugs is to stop cell cycle
progression by inhibiting DNA synthesis. Everolimus, sirolimus, tacrolimus (FK-506),
ABT-578, interferon, dexamethasone, and cyclosporine belong to this category. The siro-
limus derived compounds appear to be promising in their ability to reduce intimal thi-
ckening.
Migration inhibitors
These compounds are aimed at preventing endothelial cell migration to the inside
of the stent. Once smooth muscle cells migrate to the luminal side of the stent, they can
produce an extracellular matrix and begin to occlude blood flow. Therefore, inhibiting
their migration can have great therapeutic applications for preventing in the stent reste-
nosis. Examples of these compounds are batimastat and halofuginone. Batimastat, for
example, is a potent inhibitor of matrix metalloproteinase enzymes. It can prevent ma-
trix degradation, which is necessary for cell migration and stent invasion. If the cells
cannot move, they cannot invade the stent area.
Enhanced healing factors
Vascular endothelial growth factor promotes healing of the vasculature. In the con-
text of stents, this would heal the implantation site and reduce platelet sequestration due
to injury related chemotaxis. Nitrous oxide donor compounds may also replicate this ef-
fect. Healing of the vessel wall seems to be the gentlest approach to preventing ISR, but
healing factors are still at the early stages of development for this application.
PRODUCTS OF DRUG-ELUTING STENTS
Stents eluting anti-inflammatory agents
Because of the role of inflammatory cells in restenosis, these cells seemed to be an
optimal target in the fight against restenosis. Indeed, corticosteroids have long been shown
to reduce the influx of mononuclear cells, to inhibit monocyte and macrophage function,
and to influence smooth muscle cell proliferation (18). Nonetheless, clinical trials have
failed to demonstrate any benefit of systemic steroid therapy (19).
Stents eluting corticosteroids
Methylprednisolone (300 mg) eluting tantalum stents coated with poly (organo)
phosphazene were utilized in a porcine model. Although 96 % of the drug was released
within 24 hours, a reduction in neointimal proliferation resulted; compared to intimal
hyperplasia promoted by the polymer alone (20). Others did not observe the antireste-
notic effect of stents loaded with 0.8 mg of dexamethasone in a similar model (21).
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Tranilast-eluting stents
Tranilast, N-(3,4-dimethoxycinnamoyl) anthranilic acid, has been shown to inhibit
proliferation and migration of vascular smooth muscle cells in experimental models.
Systemic use of this agent for prevention of restenosis was tested in a large multicenter
trial and it was observed that tranilast did not improve the targeted quantitative mea-
sure of restenosis, i.e., angiographic and intravascular ultrasound or its subsequent clini-
cal implications (22).
Stents eluting immunosuppressive agents
Encouraged by the early experience with ionizing radiation therapy, researchers have
proposed sophisticated pharmacological strategies interfering with cell cycle division (10).
Xenobiotic molecules (rapamycin, FK506, cyclosporine, and analogues) and antimetabo-
lites (mycophenolate mofetil) have been utilized.
Sirolimus eluting stents. – Sirolimus is a macrolide antibiotic with potent antifungal,
immunosuppressive, and antimitotic properties. The drug is produced by cultured Strep-
tomyces hyroscopicus. Shortly after its approval, the first sirolimus-eluting stents were im-
planted in human coronary arteries.
Rapamycin analogue eluting stents. – Everolimus, [40-O-(2-hydroxyethyl)-rapamycin],
is also an inhibitor of mTOR. It has been shown to inhibit proliferation of hematopoietic
and non-hematopoietic cells. Although the immunosuppressive activity of everolimus is
2 to 3 fold lower than that of sirolimus in vitro, animal studies have shown a potent anti-
restenotic effect of everolimus given orally or via a drug-eluting stent (23).
Tacrolimus eluting stents. – Tacrolimus is a hydrophobic immunosuppressive agent
that has been used clinically to prevent renal transplant rejection. It binds to the FKBP12
protein, but its mechanism of action differs from sirolimus. Tacrolimus has been shown
to inhibit the release of proinflammatory cytokines and activation of T cells. Initial in vi-
tro and in vivo studies have failed to demonstrate the inhibition of smooth muscle cell
proliferation with tacrolimus.
Mycophenolic acid-eluting stent. – Mycophenolic acid (MPA) is the active metabolite
of mycophenolate mofetil, an antibiotic derived from cultures of the Penicillium species,
and has both antineoplastic and immunosuppressive properties. The Duraflex stent
(Avantec Vascular Devices, USA), coated with a 5-mm layer of polyhydrocarbon polymer
loaded with MPA, showed a 40 % reduction in neointimal proliferation compared to the
control in a porcine coronary model (G. Leclerc, personal communication, 2002). The in-
hibition with MPA of the coronary restenosis trial (IMPACT) is a multicenter study that
included 150 patients with de novo coronary lesions. Slow-release (45 days) and fast-re-
lease (15 days) eluting stents coated with 4.5 mg of MPA mm2 were compared with bare
Duraflex stents. Preliminary results suggest no differences in angiographic outcomes be-
tween groups, but final data are still pending.
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Paclitaxel eluting stents
Paclitaxel is a microtubule stabilizing agent with potent antitumor activity. Many
different platforms that use polymer coatings or surface modifications to cause paclita-
xel to adhere onto the stents have been utilized over the past 2 years. Paclitaxel exerts its
antiproliferative effects at concentrations much lower than those used for the treatment
of cancer (24).
Angiopeptin eluting stents
Somatostatin, an angiopeptin analogue, has been shown to reduce tissue response
to several growth factors. In humans, systemic administration of angiopeptin has im-
proved the clinical outcome after angioplasty but showed no effect in restenosis (25).
Tyrosine kinase inhibitor eluting stents
The results of clinical studies on the use of these agents are awaited.
Actinomycin D-eluting stents
Actinomycin D is an anticancer drug that selectively inhibits RNA synthesis. Clini-
cal trials using this drug were stopped prematurely because its use led to a high inci-
dence of repeat revascularization.
Stents eluting anti-thrombotic agents
Though vessel injury with resulting platelet aggregation and thrombus formation
plays a prominent role in the development of restenosis, antithrombotic pharmacologi-
cal approaches have been proven to be ineffective in preventing restenosis. Nitrous ox-
ide and glycoprotein IIb/IIIa inhibitors have been used as stent coatings, but their effi-
cacy is yet to be proved (26).
Stents eluting extracellular matrix modulators
Matrix metalloproteinases (MMP) have the ability to digest collagen and facilitate
smooth muscle cell migration. Batimastat, a non-specific MMP inhibitor, as well as other
MMP inhibitors have been shown to inhibit neointimal hyperplasia in animal models
(27). However, in human trials they have not shown significant benefits.
Stents eluting prohealing agents
There are reports suggesting that endothelialization of stents with a functional en-
dothelium reduces the restenotic process (28). In a recent study, implantation of endo-
thelial progenitor cell (EPC) capture stents showed promising results; there was no in-
crease in major adverse cardiac and cerebrovascular events (MACCE) (29). Nitric oxide,
vascular endothelial growth factor, and 17-ß-oestradiol have all been tested as prohea-
ling and antirestenotic agents, but the results are conflicting.
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FUTURE TRENDS
New solutions for the next generation of drug-eluting stents
Intense work on stent development has successfully led to the introduction of di-
verse DES (Fig. 2). Several critical breakthrough technologies account for the remarkable
progress in the field of interventional cardiology in the past three decades: intracoronary
stents have increased success rates and reduced restenosis, adjunctive antiplatelet ther-
apy has reduced periprocedural complications, and restenosis after stent placement has
been effectively treated with local radiation (30). The role of other agents with potential
benefits (e.g. statins, adenovirus-mediated arterial gene transfer, tyrosine kinase inhibi-
tors, L-arginine, abciximab, angiopeptin, r-PEG-hirudin and iloprost) as well as biode-
gradable stents may be tested in the future. The rapidly developing fields of nanotech-
nology, microelectronics, and advanced materials technology will enable the surface
engineer to design molecular-specific surfaces for a new generation of vascular devices
(31).
New coating (bioabsorbable coating). – Bioabsorbable DES is a device that could achie-
ve excellent acute and long-term results, but disappear completely within months, the-
reby avoiding the need for prolonged dual antiplatelet therapy. In the late 1990s, a bio-
absorbable (Igaki–Tamai, Japan) stent, made of a high-molecular-mass poly-L-lactic acid
(PLLA), was implanted in 15 patients (25 stents) to evaluate the feasibility, safety, and ef-
ficacy of the PLLA stent. No major cardiac event, except for repeat angioplasty, devel-
oped within 6 months. Coronary PLLA biodegradable stents are feasible, safe, and effec-
tive in humans. Long-term follow-up with more patients is required to validate the
long-term efficacy of PLLA stents (32). Everolimus eluting poly-L-lactide stent, which
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Fig. 2. Different generations of drug eluting stents.
demonstrated comparable restenotic rates with BMS and a low incidence of major ad-
verse cardiac events, suggests that there has been significant progress compared to ear-
lier prototypes (33, 34). Biotronik absorbable magnesium stent is the only stent in clinical
trials (Table II). Unlike magnesium stents, there has been little progress with iron stents,
which remain in the pre-clinical phase, and this may be partly due to the longer degra-
dation time needed and potential issues related with iron clearance (35, 36).
Complete absorbable metallic or polymeric-free platform. – The use of polymer-free stents
may have a potential long-term benefit over traditional polymeric coated DES. Tada et
al. evaluated local delivery of Biolimus A9, from a polymer-free BioFreedom stent (Table
II). BioFreedom (Biosenses, USA) stents were associated with reduced neointimal prolif-
eration compared to the polymer coated sirolimus-eluting Cypher stent. The polymer-
-free Biolimus A9 coated stent demonstrates equivalent early and superior late reduc-
tion of intimal proliferation compared to the Cypher stent in a porcine model (37). Costa
et al. (38) assessed the safety and efficacy of the novel VESTAsync-eluting stent (MIV
Therapeutics, India) combining a stainless steel platform with a nanothin-microporous
hydroxyapatite surface coating impregnated with a low polymer-free dose of sirolimus.
The novel VESTAsync-eluting stent was effective in reducing lumen loss and neointimal
hyperplasia, with no evidence of late catch-up by quantitative coronary angiography or
intravascular ultrasound.
A new technique of elution (reservoir, dual elution). – Pimecrolimus, a tacrolimus ana-
logue, has been investigated on its own, but also in combination with paclitael (Symbio
stent, Conor Medsystems, USA). It exerts multiple anti-inflammatory effects including
inhibition of IL-2 synthesis via calcineurin inhibition.
Prohealing approach + sirolimus or paclitaxel. – The Synchronnium stent (Sahajanand
Medical Technologies, India) consists of a stainless steel stent coated with a biodegrad-
able polymer incorporating heparin and sirolimus. Both drugs are released simultaneou-
sly over approximately 50 days. The initial clinical results are promising. Genistein, a
natural isoflavanoid phytoestrogen is currently under investigation in combination with
sirolimus. Flavanoids have a number of potentially beneficial characteristics including
anti-platelet aggregation, anti-inflammatory and anti-oxidant properties.
Prohealing approach (endothelial progenitor cell (EPC) capture). – An alternative approach,
concentrating on healing as opposed to SMC inhibition, is used in the Genous endothe-
lial progenitor cell (EPC) capture stent (Orbus, Neich, USA). This is a stainless steel stent
coated with murine monoclonal antihuman CD34 antibodies, which attract circulating
EPCs, thereby encouraging rapid endothelialization and reducing thrombosis. The EPC
capture stent appears effective in stable patients (39, 40) and also in the setting of acute
myocardial infarction (41).
New stent design for challenging targets such as coronary bifurcations. – The OPTIMA
new-generation DES system offers the combination of a polymer-free drug reservoir and
Carbofilm coating. It has proven antithrombotic and potentially prohealing action. The
OPTIMA (Carbostent and Implantable Devices [CID] S.r.l., Italy) key features are the ab-
sence of any polymer to carry the tacrolimus (the proprietary drug-release system with
reservoirs on the outer surface of the stent), ensuring the drug release being only tar-
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geted toward the vessel wall. Integral Carbofilm coating favors early endothelialization
of the stent thus reducing the risk of stent thrombosis (42).
New drug (less cytostatic or cytotoxic). – Batimastat is a broad spectrum MMP inhibi-
tor, non-cytotoxic and thus potentially provided controlled antagonism of the restenosis
process (43). Biocompatibles, a stent company (now owned by Abbott Vascular Devices,
USA), applied batimastat to their phosphorylcholine (PC) coated Biodivysio stent. An-
other novel target is the local delivery of anti-VEGF, which might decrease the formation
of vaso vasorum and thereby promote antheromatous plaque stability. Investigation into
the anti-VEGF bevacizumab (Avastin) eluting BiodivYsio stent (Biocampatibles Ltd.,
UK) is currently in progress (44).
CONCLUSIONS
Intense work on stent development has successfully led to the introduction of drug-
-eluting stents in 2002, as an effort to address restenosis problem. First generation DES
(sirolimus and paclitaxel eluting) was introduced first and found to be more effective
than the bare metal stent (BMS). The use of the first generation DES dealt with the prob-
lem of restenosis. But, despite early successes, uncertainty remains in the overall safety,
especially for late adverse clinical events such as stent thrombosis. Thus, the second gen-
eration (everolimus and zotarolimus eluting) stents were developed and introduced with
lower thrombosis rates. Today, in the search for improving the performance of available
DES, various developments and clinical studies are ongoing. The success of the present
DES has shifted the focus to further development toward enhancing long-term safety
and efficacy of these devices. The next generation DES will probably further improve
endothelization and rapid arterial healing.
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S A @ E T A K
Sada{njost i budu}nost stentova za restenozu koji otpu{taju lijekove
MAULIK J. PATEL, SANJAY S. PATEL, NIDHI S. PATEL i NATVARLAL M. PATEL
Stentovi koji otpu{taju lijekove (DESs) koriste se u kardiologiji za terapiju bolesti
karotidnih arterija jer zna~ajno smanjuju restenozu. Dobar DES ima polimerni sloj za ispo-
ruku lijekova. Klini~ki pokusi u kojima je ispitivano nekoliko agenasa pokazali su zna-
~ajno smanjenje restenoze nakon ugradnje stenta. Razvoj DES-a jedno je od revolucio-
narnih otkri}a u podru~ju interventne kardiologije. Idealni lijek za prevenciju restenoze
mora imati antiproliferativni i antimigracijski u~inak na stanice glatkih mi{i}a, a s druge
strane mora pove}avati endotelizaciju kako bi se sprije~ila tromboza. Osim toga, treba
u~inkovito inhibirati protuupalni odgovor nakon ozljede arterije. Iako DES zna~ajno sma-
njuje restenozu krvnih `ila, kasna tromboza i restenoza ostaju i dalje problem i predmet
brojnih istra`ivanja.
Klju~ne rije~i: stent koji otpu{ta lijek, restenoza, biorazgradljivi polimer
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